Fulminant hepatitis type B after chemotherapy in a serologically negative hepatitis B virus carrier with acute myelogenous leukemia.
We report a case of a 41-year-old man with acute myelogenous leukemia who developed fulminant hepatitis from reactivation of trace hepatitis B virus (HBV) 2 months after complete remission. Although he became positive for HB surface antigen at the onset of fulminant hepatitis, he had been negative for HBV serum markers, and only HBV DNA was detected by polymerase chain reaction (PCR) amplification on admission. The original stocks of serum samples from all blood donors were tested again for HBV DNA by PCR, and all samples were negative. This case demonstrates that testing for HBV DNA by PCR is necessary before chemotherapy, because silent HBV carriers are rare and fulminant hepatitis may be induced by chemotherapy in patients with hematologic malignancies.
Ishiga
K
K
Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Kawatani
T
T
Suou
T
T
Tajima
F
F
Omura
H
H
Idobe
Y
Y
Kawasaki
H
H
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004279:DNA, Viral / Q000097:blood; D006509:Hepatitis B / Q000139:chemically induced / Q000209:etiology*; D006515:Hepatitis B virus / Q000235:genetics / Q000254:growth & development; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy; D017093:Liver Failure / Q000821:virology*; D008297:Male; D016133:Polymerase Chain Reaction; D014775:Virus Activation / Q000187:drug effects
D000970:Antineoplastic Agents; D004279:DNA, Viral